 |
Per Bengtsson (Born 1954)
CEO and president.
Education: M.D, Ph.D. (cell biology)
Primary Experience: CEO of Probi AB (publ), R&D Manager Pharmacia/Pharmiacia&Upjohn PlasmaProducts, Medical Manager at Ferring and Development Manager at Bionor Immuno A/S.
Other assignments: Board member in Pharmavizer AB.
Number of shares: 0
Number of warrants: 0 |
 |
Maria Öhlander (Born 1968)
Vice President Clinical Development & Regulatory Affairs
Education: M Sc in Biology
Previous experience: Clinical Research Manager Pharmacia & Upjohn, Clinical Project Manager and Study Delivery Director AstraZeneca, Director Clinical Operations and Principal Project Manager Karo Bio AB.
Number of shares: 2 666
Number of warrants: 0 |
 |
Maria Sjöberg (Born 1964)
Vice President, Chief Scientific Officer, Preclinical R&D
Education: Ph.D., Associate Professor
Previous experience: R&D/Production Director SentoClone AB, Senior Scientist Astra Zeneca Biotech, Section Head/ Project Leader KaroBio AB, Group Leader Karolinska Institutet.
Number of shares: 33 750
Number of warrants: 0 |
 |
Henrik Palm (Born 1958)
Chief Financial Officer. Employed since 2011
Education: Bachelor of Business Administration, University of Gothenburg
Previous experience: Business controller within the Ericsson group (1982-2000), CFO ElektronikGruppen BK AB (publ) (2000-2009) and CFO Feelgood Svenska AB (publ) (2009-2010).
Number of shares: 0
Number of warrants: 0
|
 |
Lars Öhman (Born 1957)
Vice President Business Development. Employed by Karo Bio since 1989
Education: MBA Stockholm School of Economics. Chemical Engineering, Royal Institute of Technology.
Previous experience: Project leader and manager within Karo Bio’s research- and development organization
Number of shares: 28 660
Number of warrants: 4 548 |
